Director Daniel Mazziota sold 10,000 shares of AmpliTech Group Inc (AMPG) on June 23, 2026, reducing his total holdings to 237,743 shares. This transaction is part of a pattern of insider selling at the company, with 1 insider buy and 5 insider sells over the past year. AMPG stock, trading at $7.71 and having a GF Value of $2.14, is considered significantly overvalued with a price-to-GF-Value ratio of 3.6.

Dow Inc. (DOW) closed down 3.13% in the latest trading session, underperforming the broader market and the Basic Materials sector over the past month. Despite this, the company holds a Zacks Rank #1 (Strong Buy) due to recent upward revisions in analyst estimates, with strong projected earnings and revenue growth for its upcoming report and the full year. The stock also shows an attractive valuation with a Forward P/E of 11.6 and a PEG ratio of 0.21, both discounted compared to its industry average.

Travelzoo (NASDAQ: TZOO) has announced a new Club Offer for U.S. members: an $899 all-inclusive vacation to New Mexico with flights. This special package includes flights, five nights of accommodations at a newly renovated Kimpton resort in Riviera Maya, airport transfers, and all meals and drinks. The offer provides access to luxury at significantly reduced prices for Travelzoo's 30 million members.

Widepoint COO Todd Dzyak sold 10,000 shares of the company's common stock for $175,000, executed at $17.50 per share, as the stock trades near its 52-week high after a significant gain. Following this transaction, Dzyak retains 125,436 shares and 9,714 stock options. InvestingPro analysis suggests Widepoint may be overvalued, despite recent positive Q1 2026 earnings and a "buy" rating from AmerX.

Charles River Laboratories (CRL) recently announced a collaboration with Eli Lilly's TuneLab, an AI/ML-driven drug discovery platform, to provide nonclinical testing services. This partnership integrates Charles River into an AI-enabled ecosystem, potentially enhancing its role in preclinical research, especially in data-rich areas like cell and gene therapies. The move aims to offset slower revenue growth and address the emerging risk posed by the accelerated adoption of non-animal testing methods.

Fastenal (FAST) has extended its key credit facilities and appointed a new board member, signaling financial flexibility and governance changes. While analysts peg the stock as slightly undervalued at $46.49, its high P/E ratio of 40.9x compared to the industry average of 24.7x suggests a premium valuation that leaves little room for error if growth expectations are not met. Investors are urged to consider underlying data, risks like inventory levels and tariff pressures, and mixed signals before making investment decisions.

Addex Therapeutics announced its Q1 2026 financial results, highlighting the progress of its spin-out Neurosterix in Phase 1 clinical development for NTX-253, an M4 PAM for schizophrenia. The report detailed key financial data, including a net loss of CHF 1.7 million and decreased cash and cash equivalents, and provided an update on other pipeline candidates. The company also announced a conference call to discuss these results.

Ulta Beauty and NielsenIQ have collaborated on a consumer study titled “Smart Beauty: AI, Personalization & the Gen Alpha Consumer,” exploring the beauty buying habits of Gen Alpha. The research indicates that Gen Alpha balances online discovery with in-person validation, frequently uses personalization tools, and is influenced by parental guidance. This partnership aims to leverage data-driven insights to evolve Ulta Beauty’s retail experiences and digital innovation for younger consumers.

Richard Dalzell, a Director at Intuit Inc (INTU), sold 284 shares of the company on June 23, 2026. This transaction reduces his total holdings to 11,758 shares. Intuit Inc, known for products like TurboTax and QuickBooks, showed a market price of $262.32 per share at the time of sale, making it significantly undervalued compared to its GuruFocus Value of $809.91.

D Bidzos, Executive Chairman, President, and CEO of VeriSign Inc (VRSN), sold 3,300 shares of the company on June 23, 2026, reducing his total holdings to 429,439.0301 shares. Over the last year, Bidzos has sold 130,200 shares, contributing to a total of 46 insider sells versus 3 buys for VeriSign Inc. The stock is currently trading at $248.53, and its price-to-GF-Value ratio of 0.93 indicates it is fairly valued.